Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2740-2750

  Roh, Ju Won ^a,d   Huang, Jie ^a   Hu, Wei ^a   Yang, Xiaoyun ^a   Jennings, Nicholas B ^a   Sehgal, Vasudha ^e   HwaSohn, Bo ^e   Han, Hee Dong ^a   Lee, Sun Joo ^a,f   Thanapprapasr, Duangmani ^a,g   Bottsford Miller, Justin ^a   Zand, Behrouz ^a   Dalton, Heather J ^a   Previs, Rebecca A ^a   Davis, Ashley N ^a   Matsuo, Koji ^a,c   Lee, Ju Seog ^e   Ram, Prahlad ^e   Coleman, Robert L ^a   Sood, Anil K ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Departments of Systems Biology   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Department of Obstetrics and Gynecology Dongguk University   (United States)

^e Genetic Regulatory Networks   (United States)

^f Konkuk University   (South Korea)

^g MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; OLARATUMAB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRANSCRIPTOME;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TREATMENT DURATION; UTERUS CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UTERINE NEOPLASMS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901020811     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2507     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 2006;4:459-68.
3. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20.
4. Heldin C.H.Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
5. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-Activated ligand for the PDGF alphareceptor. Nat Cell Biol 2000;2:302-9.
6. Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, Shioi A, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclindependent kinase 2. Circ Res 1996;79:757-64.
7. Ekman S, Thuresson ER, Heldin CH, Ronnstrand L. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. Oncogene 1999;18:2481-8.
8. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997;22:267-72.
9. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999;13:2400-11.
10. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997;124:2691-700.
11. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001;80:1-38.
12. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-3.
13. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993;53:4550-4.
14. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549-54.
15. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-7.
16. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1.
17. Barnhill RL, Xiao M, Graves D, Antoniades HN. Expression of plateletderived growth factor (PDGF)-A, PDGF-B and the PDGF-Alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 1996;135:898-904.
18. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of platelet-derived growth factor-Alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003;120:107-12.
19. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788- 95.
20. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9.
21. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005;4:369-79.
22. Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the plateletderived growth factor receptor alpha. Cancer 2010;116:1018-26.
23. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz- Pena GN, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15:3770-80.
24. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009;101:1193-205.
25. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95.
26. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009;124:1045-53.
27. Komurov K, Dursun S, Erdin S, Ram PT. Software NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 2012;13:282-91.
28. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998;184:44-52.
29. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241-57.
30. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem 2007;282:445-53.
31. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Plateletderived growth factor receptor-Alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007;6:1932-41.
32. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
33. Li Z, Min W, Gou J. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression ofMAPK kinase pathways. Cancer Chemother Pharmacol 2013;72:1001-11.
34. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, et al. Platelet-derived growth factor receptor alpha (PDGFRalpha) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 2014;132:166-75.
35. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-84.